INVO Bioscience Progresses in Developing Market for INVOcell in Hong Kong and Macao
MEDFORD, Mass., Feb. 28, 2018 /PRNewswire/ — INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, the INVOcell™, announced today a distribution agreement for developing the markets in Hong Kong and Macao for INVOcell.
There are 10 in-vitro fertilization (IVF) centers in Hong Kong performing approximately 11,000 treatment cycles annually. It is estimated that there are approximately 150,000 infertile couples in the Hong Kong area. With just over 7 percent of fertility cases being treated, Hong Kong and Macao with over 8 million people represent a large market opportunity that can benefit from the effective and cost-efficient treatment that utilizing the INVOcell offers.
INVO Bioscience has established an agreement with a major Hong Kong-based medical device distributor to serve this large and growing market in the Hong Kong area. INVO Bioscience has coordinated training sessions on the INVO Procedure by leading North American physicians and embryologists in the Hong Kong market.Approximately 70 fertility physicians and embryologists have recently been trained; 10 of the doctors just last month.
Katie Karloff, Chief Executive Officer of INVO Bioscience, said, “We are pleased with the progress that is being made in preparing the Hong Kong region for the rollout of the INVO Procedure. All relevant regulatory requirements been met and we are working with a leading distribution partner to develop the market opportunity. We expect that as the reputation of INVOcell develops as an effective means of treating infertility, our business will grow in a consistent and deliberate manner.”
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (“ART”). The INVOcell is the first Intravaginal Culture (“IVC”) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (“IVF”) and Intrauterine Insemination (“IUI”). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
INVO Bioscience, Inc.
Kathleen Karloff, CEO
978-878-9505 ext. 504